Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

Inclusion Criteria:

* Histologically or cytologically proved stage IV or pleural stage III NSCLC (neoplastic pleurisy confirmed).
* Metastatic relapses allowed if asymptomatic.
* Progressive disease during or after a standard first line platinum-based chemotherapy (without taxotere or alimta)
* Only one chemotherapeutic line including adjuvant and neo adjuvant treatment.
* Irradiation allowed if \< 25% bone medulla . It may be ended 2 weeks before the second line treatment.
* At least one measurable target lesion according to recist criteria in non previously irradiated area.
* Performance status \<=2
* Age between 18 and 70 years
* Life expectancy \> 12 weeks.
* Normal hepatic function
* Normal renal function
* Normal serum calcium
* Absolute neutrophil count\>1.5 gigal/l,platelets\>100 gigal/l,haemoglobin\>9.0 g/dl
* Written informed consent

Exclusion Criteria:

* SCLC, bronchioli-alveolar and neuro-endocrine carcinoma.
* Symptomatic brain metastases.
* Superior vena cava syndrome.
* Uncontrolled fluid retention in the third space (pleural or ascitic collection)
* Prior chemotherapy without platin
* Other concomitant diseases: heart failure, angina pectoris, tachyarrythmia, recent myocardial infarction, active infections.
* Peripheral neuropathy grade ≥ 2.
* Past or concomitance of another cancer except baso-cellular carcinoma of the skin or in situ cervical carcinoma.
* Hypersensitivity to docetaxel or polysorbate 80.
* Unability or unwillingness to take folic acid, vitamin B12 supplementation or corticosteroids.
* Pregnancy or breast feeding.
* Follow-up of the patient impossible.
* Prisoners